Advertisement

Topics

Immunomic Therapeutics, Inc. Company Profile

13:14 EST 17th December 2018 | BioPortfolio

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing next generation vaccines based on its patented LAMP™ Technology platform. LAMP-Vax™ vaccine technology has the potential to significantly increase the effectiveness of the immune response to nucleic acid vaccines while simplifying overall vaccine design and delivery, yielding safer, more cost-effective human and animal therapies. Our LAMP constructs have been validated in human clinical trials for cancer and have been applied to a wide breadth of targets including allergy and infectious diseases.


News Articles [693 Associated News Articles listed on BioPortfolio]

Immunomic Therapeutics to Present at the 2018 BIO Investor Forum

Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company will present at the 2018 BIO Investor Forum being held...

Immunomic Therapeutics CEO to Present at Precision Medicine World Conference (PMWC): Emerging Therapeutics Showcase

Presentation to Highlight UNITE Potential Capabilities in Immuno-Oncology Tomorrow, Dr. William Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, I...

Tomorrow: Immunomic Therapeutics CEO at Outsourcing in Clinical Trials Mid-Atlantic

ITI Founder & CEO will discuss new developments in cancer immunotherapy Tomorrow, Bill Hearl, Ph.D., Founder and Chief Executive Officer (CEO) of Immunomic Therapeu...

Immunomic Therapeutics CEO to Present at NYC Oncology Investor Conference

To Discuss UNITE Technology Application in Oncology Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, today announced that the compan...

Immunomic Therapeutics Senior Vice President of R&D to Participate in Bio+Tech Conference

Sr. VP of R&D will discuss lysosomal targeting technology as applied in cancer immunotherapy Tomorrow, Teri Heiland, Ph.D., Senior Vice President of Research and De...

Immunomic Therapeutics CEO to Present at Immuno-Oncology Summit

Presentation to Highlight the Challenges of Viral Targets in Cancer Tomorrow, Dr. Bill Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, Inc. will present...

Immunomic Therapeutics Scientist to Present at the Society for NeuroOncology 2018 Annual Meeting

On Friday, November 16, Immunomic Therapeutics Inc. (ITI) Scientist Amit Adhikara will present at the Society for NeuroOncology 2018 Annual Meeting in New Orleans. The presentatio...

Immunomic Therapeutics CEO to Join Panel at 18th Annual Biotech in Europe Forum

Panel to Highlight Advanced Therapeutics for Oncology Tomorrow, William Hearl, Ph.D., Chief Executive Officer (CEO) of Immunomic Therapeutics, Inc., will participate in a pane...

PubMed Articles [458 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

RNA-targeted therapeutics for lipid disorders.

To summarize recent developments in the field of RNA-directed therapeutics targeting lipid disorders that are not effectively managed.

A Review of Therapeutics in Clinical Development for Respiratory Syncytial Virus and Influenza in Children.

Respiratory syncytial virus (RSV) and influenza are important viral pathogens worldwide. Children, in particular, bear considerable burdens of morbidity and mortality associated with these viruses. Th...

Pharmacokinetic Analysis of Intraocular Penetration of Latanoprost Solutions with Different Preservatives in Human Eyes.

Eyes on New Product Development.

Clinical Trials [164 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1286 Associated Companies listed on BioPortfolio]

Immunomic Therapeutics, Inc.(ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These inve...

Immunomic Therapeutics (ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the LAMP-based nucleic acid immunotherapy platforms. These i...

Immunomic Therapeutics, Inc. (ITI)

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing ne...

Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company headquartered in Hershey, PA with lab facilities in Rockville, MD. ITI is developing ne...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Immunomic Therapeutics, Inc." on BioPortfolio

We have published hundreds of Immunomic Therapeutics, Inc. news stories on BioPortfolio along with dozens of Immunomic Therapeutics, Inc. Clinical Trials and PubMed Articles about Immunomic Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Immunomic Therapeutics, Inc. Companies in our database. You can also find out about relevant Immunomic Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Vaccine
A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one ...


Corporate Database Quicklinks



Searches Linking to this Company Record